Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | CHIEF MEDICAL OFFICER | October 01, 2026 | October 02, 2026 |
| Verve Therapeutics, Inc.VERV · Entity 11259 | 10% owner | June 16, 2021 | June 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,059 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 1,051 · Balance 19,059 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.51 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.51 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Verve Therapeutics, Inc.
Report date June 16, 2021 · Filed June 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 409,626 |
Reported balance
Holding disclosure · report date 2021-06-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 409,626 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2024 Filed Apr 3, 2024 20:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 9,426 | $13.23 | $124,684.30 |
DisclosureSEC source: 0001415889-24-009999 · form4-04032024_080444.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.62 to $13.55 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 442 | $0.60 | $265.20 |
DisclosureSEC source: 0001415889-24-009999 · form4-04032024_080444.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2024 Filed Jun 7, 2024 20:39 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016005 · form4-06072024_080653.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 27, 2024 Filed Jun 7, 2024 20:39 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001415889-24-016005 · form4-06072024_080653.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-26 F1 · derivative.exercise_date: The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 00:34 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 4,116 | $6.10 | $25,101.84 |
DisclosureSEC source: 0001415889-24-008689 · form4-03202024_120307.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,469 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.94 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:34 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008689 · form4-03202024_120307.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,300 Underlying: Common Stock · 13,100 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:34 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008689 · form4-03202024_120307.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,504 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001415889-24-006623 · form4-03052024_090335.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,442 Underlying: Common Stock · 5,504 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $7.75 | $77,469.00 |
DisclosureSEC source: 0001415889-24-006623 · form4-03052024_090335.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,485 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:21 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,504 | $0.60 | $3,302.40 |
DisclosureSEC source: 0001415889-24-006623 · form4-03052024_090335.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:32 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $4.80 | $47,991.00 |
DisclosureSEC source: 0001415889-24-002531 · form4-02052024_090232.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,981 F1 · kind: The sale reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.59 to $4.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:38 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $5.74 | $57,352.00 |
DisclosureSEC source: 0001209191-24-000801 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,981 F1 · kind: The sale reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.15 to $5.97 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The reported total includes an additional 1,086 shares of the issuer's stock that were acquired by the reporting person through the issuer's employee stock purchase plan in exempt transactions pursuant to Rule 16b3(c). Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unit (RSU) · Derivative | 60,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057407 · doc4.xml · derivative · entry 4 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,773 Underlying: Common Stock · 60,773 shares Expires 2025-12-01 F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: 48,792 restricted stock units will vest on December 1, 2024 and 11,981 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 107,400 | Not disclosed Strike: $20.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-057407 · doc4.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,400 shares Expires 2032-03-14 F6 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 107,400 shares of Common Stock of the Issuer and in exchange issued to the reporting person 33,561 restricted stock units. F5 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 15, 2022 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,600 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-057407 · doc4.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,600 shares Expires 2031-03-01 F4 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,600 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,463 restricted stock units. F3 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $20.25 | Not disclosed |
DisclosureSEC source: 0001209191-23-057407 · doc4.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2030-03-24 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 60,000 shares of Common Stock of the Issuer and in exchange issued to the reporting person 18,749 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 25, 2020 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 15,000 | $10.60 | $158,973.00 |
DisclosureSEC source: 0001209191-23-041616 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,895 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.28 to $10.77 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 15,000 | $11.13 | $166,963.50 |
DisclosureSEC source: 0001209191-23-034648 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,895 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.62 to $11.36 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2023 Filed May 8, 2023 23:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 653 | $10.00 | $6,530.00 |
DisclosureSEC source: 0001209191-23-028111 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,895 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. Read SEC document |
| May 03, 2023 Filed May 4, 2023 00:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 24,697 | $10.14 | $250,365.84 |
DisclosureSEC source: 0001209191-23-027190 · doc4.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.37 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 02, 2023 Filed May 4, 2023 00:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,513 | $10.00 | $55,133.86 |
DisclosureSEC source: 0001209191-23-027190 · doc4.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,245 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 4, 2023 00:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 24,967 | $10.00 | $249,767.37 |
DisclosureSEC source: 0001209191-23-027190 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,758 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 17, 2022 by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.07 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unite (RSU) · Derivative | 52,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019662 · doc4.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,400 Underlying: Common Stock · 52,400 shares Expires 2027-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 78,600 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001209191-23-019662 · doc4.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,600 Underlying: Common Stock · 78,600 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 22:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 9,235 | $10.02 | $92,491.30 |
DisclosureSEC source: 0001209191-23-007597 · doc4.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,725 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.11 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,763 | $10.03 | $37,745.15 |
DisclosureSEC source: 0001209191-23-007597 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,960 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2023 Filed Feb 2, 2023 23:32 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 267 | $10.00 | $2,670.00 |
DisclosureSEC source: 0001209191-23-006397 · doc4.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,723 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 23:32 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,705 | $10.02 | $57,140.14 |
DisclosureSEC source: 0001209191-23-006397 · doc4.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,990 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.03 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 23:32 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 200 | $10.00 | $2,000.00 |
DisclosureSEC source: 0001209191-23-006397 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,695 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 22:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001209191-22-060547 · doc4.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-12-06 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on January 7, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 21:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 107,400 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0001209191-22-019686 · doc4.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 107,400 shares Expires 2032-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2022 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 23:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,300 | $33.55 | $110,725.56 |
DisclosureSEC source: 0001209191-21-046830 · doc4.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,895 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.21 to $34.17 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 23:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 39,866 | $32.68 | $1,302,928.52 |
DisclosureSEC source: 0001209191-21-046830 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,195 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.19 to $33.16 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 430 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2021. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:03 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,600 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017876 · doc4.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 65,600 shares Expires 2031-03-01 F2 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 21:53 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,365 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-064663 · doc4.xml · derivative · entry 5 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,400 Underlying: Common Stock · 1,365 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 21:53 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 365 | $59.00 | $21,534.23 |
DisclosureSEC source: 0001209191-20-064663 · doc4.xml · nonDerivative · entry 4 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,402 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.86 to $59.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 21:53 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 286 | $58.02 | $16,592.89 |
DisclosureSEC source: 0001209191-20-064663 · doc4.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,767 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.74 to $58.395 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 21:53 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 714 | $56.76 | $40,526.93 |
DisclosureSEC source: 0001209191-20-064663 · doc4.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,053 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.66 to $57.37 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 21, 2020 Filed Dec 21, 2020 21:53 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,365 | $2.19 | $2,989.35 |
DisclosureSEC source: 0001209191-20-064663 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 740 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 42,880 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-034101 · doc4.xml · derivative · entry 6 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,765 Underlying: Common Stock · 42,880 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 131,147 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-034101 · doc4.xml · derivative · entry 5 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,946 Underlying: Common Stock · 131,147 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 2, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 365 | $27.98 | $10,212.70 |
DisclosureSEC source: 0001209191-20-034101 · doc4.xml · nonDerivative · entry 4 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,662 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,000 | $27.17 | $27,174.00 |
DisclosureSEC source: 0001209191-20-034101 · doc4.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,027 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.82 to $27.43 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 42,880 | $2.19 | $93,907.20 |
DisclosureSEC source: 0001209191-20-034101 · doc4.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:58 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 131,147 | $0.60 | $78,688.20 |
DisclosureSEC source: 0001209191-20-034101 · doc4.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-20-021319 · doc4.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.